Compare NRO & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRO | RPID |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.6M | 204.3M |
| IPO Year | 2003 | 2021 |
| Metric | NRO | RPID |
|---|---|---|
| Price | $3.01 | $2.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 241.5K | 196.8K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,587,000.00 |
| Revenue This Year | N/A | $19.12 |
| Revenue Next Year | N/A | $18.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.74 |
| 52 Week Low | $2.74 | $2.01 |
| 52 Week High | $3.37 | $4.94 |
| Indicator | NRO | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 45.08 |
| Support Level | $2.91 | $2.36 |
| Resistance Level | $3.10 | $2.43 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 70.45 | 71.77 |
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.